**Peer Review Journal ** DOI on demand of Author (Charges Apply) ** Fast Review and Publicaton Process ** Free E-Certificate to Each Author

Current Issues
     2026:3/2

International Journal of Pharma Growth Research Review

ISSN: (Print) | 3049-0421 (Online) | Impact Factor: 8.51 | Open Access

Arrangement incident and confirmation of antagonistic-malignancy drug Erlotinib in advertised drug portion of drug or other consumable form by RP-HPLC

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF)

Abstract

A novel converse-aspect souped up liquid chromatographic (HPLC) method for the perseverance of Erlotinib and allure Drug Portion of drug or other consumable form has happened increased and approved as per ICH Directions. Erlotinib was divided on a Proportion Coordinated outfit (C18) RP Line, 250 mm x 4.6 mm, 5µm accompanying a arrangement of Phosphate Safeguard and Intoxicating in the percentage of 46:54%v/v (pH-3.2) regulated by adding of 0.1% orthophosphoric acid resolution) as travelling state at a flow rate of 1.0 mL brief time period-1. The discharge was listened by UV discovery at 206 nm. Measurement plots were uninterrupted in the range of 60 to 140 μg mL-1 and the LOD and LOQ were 0.08 and 0.24 μg mL-1, individually. All method is grown and substantiated as per Worldwide Board for Agreement (ICH) directions. The projected procedure is healthy, impressionable, breakneck and profitable and beneficial in the domains place supervisory instrumentalities advise HPLC examining form.

How to Cite This Article

Shaik Khan Khasim, Abdul Abrar (2024). Arrangement incident and confirmation of antagonistic-malignancy drug Erlotinib in advertised drug portion of drug or other consumable form by RP-HPLC . International Journal of Pharma Growth Research Review (IJPGARR), 1(1), 05-07.

Share This Article: